比較分析TACE手術(shù)與TACE聯(lián)合索拉非尼在肝癌治療中對(duì)腫瘤相關(guān)血管的影響
發(fā)布時(shí)間:2022-01-25 12:06
目的:通過(guò)回顧性研究,分析比較單純接受TACE手術(shù)與接受TACE聯(lián)合索拉非尼治療后的晚期肝癌患者中,腫瘤相關(guān)血管的改變。方法:回顧性的研究與分析我院20名晚期肝癌患者的相關(guān)臨床數(shù)據(jù)。每位患者所接受的治療全部根據(jù)自己的意愿決定:在此基礎(chǔ)之上,綜合考慮患者的治療意愿和具體病情之后,劃分為接受聯(lián)合治療的TS組(TACE聯(lián)合索拉非尼Sorafenib)(n=10)和單純接受TACE手術(shù)治療的TACE組(n=10)。數(shù)字減影血管造影圖由兩位對(duì)患者治療方法放射科醫(yī)生進(jìn)行測(cè)量分析。在血管造影圖中,借助相關(guān)的軟件儀器,可以分別將肝總動(dòng)脈、肝固有動(dòng)脈、肝右動(dòng)脈、脾動(dòng)脈、胃左動(dòng)脈、胃十二指腸動(dòng)脈、門(mén)靜脈的血管直徑及腫瘤微血管數(shù)目測(cè)量出來(lái);在獲得以上的數(shù)據(jù)之后,對(duì)兩組接受治療前后的數(shù)據(jù)以及兩組之間的數(shù)據(jù)進(jìn)行綜合分析和比較,結(jié)果:在TS組中,肝總動(dòng)脈、肝固有動(dòng)脈、肝右動(dòng)脈的血管直徑和腫瘤微血管數(shù)目在服用索拉非尼之后顯著的減少了(P<0.05),與此同時(shí),脾動(dòng)脈、胃左動(dòng)脈、胃十二指腸動(dòng)脈的血管直徑在治療前后并沒(méi)有顯著改變(P>0.05);在TACE組中,以下這些血管直徑在接受治療前后并沒(méi)有顯著的變化...
【文章來(lái)源】:廈門(mén)大學(xué)福建省 211工程院校 985工程院校 教育部直屬院校
【文章頁(yè)數(shù)】:58 頁(yè)
【學(xué)位級(jí)別】:碩士
【部分圖文】:
圖2.TS組服藥前后腫瘤相關(guān)血管造影圖片??
?第三章結(jié)果???3.2.2?TACE組服藥前后相關(guān)血管數(shù)據(jù)分析:??在TACE組中,除了肝右動(dòng)脈以外,兩次TACE前后的其他腫瘤相關(guān)血管直徑??并沒(méi)有顯著的減。涸诘诙危裕粒茫攀中g(shù)的血管造影時(shí),所得到的數(shù)據(jù)中在與第??一次的比較之后得出,肝總動(dòng)脈前后血管直徑的差異不具備統(tǒng)計(jì)學(xué)意義。具體數(shù)??據(jù)如下:肝總動(dòng)脈(0.521?±0.0272?cm?w.0.502±0.0329?cm,?P>0.05);肝固有動(dòng)脈??(0.450±0.0376cmw.?0.407±0.0419cm,P>0.05);然而,肝右動(dòng)脈在第二次造影所??測(cè)得的血管直徑與第一次相比較時(shí),顯著減小了。?(0.110±0.0104?cm?vs.??0.087±0.00335?cm,?P<0.05),詳見(jiàn)圖?3。??除此以外,非腫瘤相關(guān)血管在TACE組中,經(jīng)過(guò)治療后,前后所得血管直徑??數(shù)據(jù)的差異也不具備統(tǒng)計(jì)學(xué)意義。具體如下:胃左動(dòng)脈(0.300±0.0183?cm??0.301±0.0211?cm,?P>0.05);胃十二指腸動(dòng)脈(0.352±0.0202?cm?w.?0.338士0.0212??cm,P>0.05);脾動(dòng)脈(0.602±0.0262〇11以.0.61±0.0277cm,P>0.05),詳見(jiàn)圖?3〇??
Angiograph?after?TACE??圖4.TACE組治療前后血管改變??Pic?G,H5IJ:?angiograph?before?TACE;?Pic?K,L,M,N:angiograph?after?TACE;Pic??G,K:?Red?arrow?and?Blue?arrow?respectively?indicates?proper?hepatic?artery?an??d?gastroduodenal?artery;Pic?H,L:?Red?arrow?and?Blue?arrow?respectively?indicat??es?left?gastric?artery?and?splenic?artery;Pic?I5M:?Red?arrow,Blue?arrow?and?Bla??ck?arrow?respectively?indicates?hepatic?artery?branches,left?gastric?artery?and?spl??enic?artery;Pic?J,N:?Red?arrow?indicates?hepatic?artery?branches;??小圖G,H,I,J:?TACE術(shù)前的血管造影圖;小圖K,L,M,N:?TACE術(shù)后的血管??造影圖;小圖G,K:紅色箭頭,藍(lán)色箭頭分別指向肝固有動(dòng)脈和胃十二指腸動(dòng)脈;??
【參考文獻(xiàn)】:
期刊論文
[1]New advances in hepatocellular carcinoma[J]. Sonia Pascual,Iván Herrera,Javier Irurzun. World Journal of Hepatology. 2016(09)
[2]Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system[J]. Kichang Han,Jin Hyoung Kim. World Journal of Gastroenterology. 2015(36)
[3]Staging systems for hepatocellular carcinoma: Current status and future perspectives[J]. Akiyoshi Kinoshita,Hiroshi Onoda,Nao Fushiya,Kazuhiko Koike,Hirokazu Nishino,Hisao Tajiri. World Journal of Hepatology. 2015(03)
[4]我國(guó)肝癌研究的現(xiàn)狀與前景[J]. 呂桂帥,陳磊,王紅陽(yáng). 生命科學(xué). 2015(03)
[5]Histopathology of hepatocellular carcinoma[J]. Manuel Schlageter,Luigi Maria Terracciano,Salvatore D’Angelo,Paolo Sorrentino. World Journal of Gastroenterology. 2014(43)
[6]巴塞羅那分期挑戰(zhàn)下的中國(guó)肝癌治療[J]. 王征,周儉. 肝膽外科雜志. 2014(04)
[7]Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy?[J]. Julia Neperud,Armeen Mahvash,Naveen Garg,Ravi Murthy,Janio Szklaruk. World Journal of Radiology. 2013(06)
[8]HIF-1α基因沉默對(duì)大鼠肝癌CBRH-7919細(xì)胞p27和Ki67表達(dá)的影響[J]. 許林鋒,倪嘉延,陳耀庭,孫宏亮,吳裕丹. 中國(guó)病理生理雜志. 2012(10)
[9]乏氧對(duì)人牙周膜細(xì)胞HIF-1α及VEGF表達(dá)的影響[J]. 侯超,唐開(kāi)亮,楊丕山,張盼盼,孫靜,李紓. 上?谇会t(yī)學(xué). 2010(03)
[10]Quantitative analysis of hepatic hypoxia-inducible factor-1α and its abnormal gene expression during the formation of hepatocellular carcinoma[J]. Deng-Fu Yao,Hua Jiang,Min Yao,Yue-Ming Li,Wen-Jing Gu,Yu-Cheng Shen, Li-Wei Qiu,Wei Wu,Xin-Hua Wu and Wen-Li Sai Research Center of Clinical Molecular Biology,Department of Laboratory Science,and Department of Oncology,Affiliated Hospital of Nantong University,Nantong 226001, China;Third Department of Medicine,Jiaonan People’s Hospital,Jiaonan 266400,China. Hepatobiliary & Pancreatic Diseases International. 2009(04)
本文編號(hào):3608507
【文章來(lái)源】:廈門(mén)大學(xué)福建省 211工程院校 985工程院校 教育部直屬院校
【文章頁(yè)數(shù)】:58 頁(yè)
【學(xué)位級(jí)別】:碩士
【部分圖文】:
圖2.TS組服藥前后腫瘤相關(guān)血管造影圖片??
?第三章結(jié)果???3.2.2?TACE組服藥前后相關(guān)血管數(shù)據(jù)分析:??在TACE組中,除了肝右動(dòng)脈以外,兩次TACE前后的其他腫瘤相關(guān)血管直徑??并沒(méi)有顯著的減。涸诘诙危裕粒茫攀中g(shù)的血管造影時(shí),所得到的數(shù)據(jù)中在與第??一次的比較之后得出,肝總動(dòng)脈前后血管直徑的差異不具備統(tǒng)計(jì)學(xué)意義。具體數(shù)??據(jù)如下:肝總動(dòng)脈(0.521?±0.0272?cm?w.0.502±0.0329?cm,?P>0.05);肝固有動(dòng)脈??(0.450±0.0376cmw.?0.407±0.0419cm,P>0.05);然而,肝右動(dòng)脈在第二次造影所??測(cè)得的血管直徑與第一次相比較時(shí),顯著減小了。?(0.110±0.0104?cm?vs.??0.087±0.00335?cm,?P<0.05),詳見(jiàn)圖?3。??除此以外,非腫瘤相關(guān)血管在TACE組中,經(jīng)過(guò)治療后,前后所得血管直徑??數(shù)據(jù)的差異也不具備統(tǒng)計(jì)學(xué)意義。具體如下:胃左動(dòng)脈(0.300±0.0183?cm??0.301±0.0211?cm,?P>0.05);胃十二指腸動(dòng)脈(0.352±0.0202?cm?w.?0.338士0.0212??cm,P>0.05);脾動(dòng)脈(0.602±0.0262〇11以.0.61±0.0277cm,P>0.05),詳見(jiàn)圖?3〇??
Angiograph?after?TACE??圖4.TACE組治療前后血管改變??Pic?G,H5IJ:?angiograph?before?TACE;?Pic?K,L,M,N:angiograph?after?TACE;Pic??G,K:?Red?arrow?and?Blue?arrow?respectively?indicates?proper?hepatic?artery?an??d?gastroduodenal?artery;Pic?H,L:?Red?arrow?and?Blue?arrow?respectively?indicat??es?left?gastric?artery?and?splenic?artery;Pic?I5M:?Red?arrow,Blue?arrow?and?Bla??ck?arrow?respectively?indicates?hepatic?artery?branches,left?gastric?artery?and?spl??enic?artery;Pic?J,N:?Red?arrow?indicates?hepatic?artery?branches;??小圖G,H,I,J:?TACE術(shù)前的血管造影圖;小圖K,L,M,N:?TACE術(shù)后的血管??造影圖;小圖G,K:紅色箭頭,藍(lán)色箭頭分別指向肝固有動(dòng)脈和胃十二指腸動(dòng)脈;??
【參考文獻(xiàn)】:
期刊論文
[1]New advances in hepatocellular carcinoma[J]. Sonia Pascual,Iván Herrera,Javier Irurzun. World Journal of Hepatology. 2016(09)
[2]Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system[J]. Kichang Han,Jin Hyoung Kim. World Journal of Gastroenterology. 2015(36)
[3]Staging systems for hepatocellular carcinoma: Current status and future perspectives[J]. Akiyoshi Kinoshita,Hiroshi Onoda,Nao Fushiya,Kazuhiko Koike,Hirokazu Nishino,Hisao Tajiri. World Journal of Hepatology. 2015(03)
[4]我國(guó)肝癌研究的現(xiàn)狀與前景[J]. 呂桂帥,陳磊,王紅陽(yáng). 生命科學(xué). 2015(03)
[5]Histopathology of hepatocellular carcinoma[J]. Manuel Schlageter,Luigi Maria Terracciano,Salvatore D’Angelo,Paolo Sorrentino. World Journal of Gastroenterology. 2014(43)
[6]巴塞羅那分期挑戰(zhàn)下的中國(guó)肝癌治療[J]. 王征,周儉. 肝膽外科雜志. 2014(04)
[7]Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy?[J]. Julia Neperud,Armeen Mahvash,Naveen Garg,Ravi Murthy,Janio Szklaruk. World Journal of Radiology. 2013(06)
[8]HIF-1α基因沉默對(duì)大鼠肝癌CBRH-7919細(xì)胞p27和Ki67表達(dá)的影響[J]. 許林鋒,倪嘉延,陳耀庭,孫宏亮,吳裕丹. 中國(guó)病理生理雜志. 2012(10)
[9]乏氧對(duì)人牙周膜細(xì)胞HIF-1α及VEGF表達(dá)的影響[J]. 侯超,唐開(kāi)亮,楊丕山,張盼盼,孫靜,李紓. 上?谇会t(yī)學(xué). 2010(03)
[10]Quantitative analysis of hepatic hypoxia-inducible factor-1α and its abnormal gene expression during the formation of hepatocellular carcinoma[J]. Deng-Fu Yao,Hua Jiang,Min Yao,Yue-Ming Li,Wen-Jing Gu,Yu-Cheng Shen, Li-Wei Qiu,Wei Wu,Xin-Hua Wu and Wen-Li Sai Research Center of Clinical Molecular Biology,Department of Laboratory Science,and Department of Oncology,Affiliated Hospital of Nantong University,Nantong 226001, China;Third Department of Medicine,Jiaonan People’s Hospital,Jiaonan 266400,China. Hepatobiliary & Pancreatic Diseases International. 2009(04)
本文編號(hào):3608507
本文鏈接:http://sikaile.net/yixuelunwen/zlx/3608507.html
最近更新
教材專(zhuān)著